FAILURE TO ACHIEVE THERAPEUTIC ACETYL SALICYLIC ACID (ASA) CONCENTRATIONS IN CHILDREN WITH KAWASAKI DISEASE (KD)

G. Koren,S. Macleod

DOI: https://doi.org/10.1203/00006450-198404001-00368

IF: 3.953

1984-04-01

Pediatric Research

Abstract:ASA is the most widely used drug in KD. Several studies have demonstrated that satisfactory reversal of clinical symptoms and signs is achieved only after dosage in excess of 100 mg/kg/day. Low dose ASA treatment has been shown ineffective in prevention of coronary aneurysm formation. We retrospectively assessed 49 children (33 m:16 f) aged 2.6 ± 1.8 yrs (range 8 mo-8 yrs) who had KD and were treated with ASA 30-180 mg/kg/day. There was a good correlation between dosage and salicylate concentrations (r=0.69; p<0.001); however, wide variability existed. At dosage below 80 mg/kg/day no ASA serum concentration exceeded 20 mg/dl. In children receiving 100-110 mg/kg/day, 55% of the serum concentrations were below 20 mg/dl. A similar pattern was seen with doses >120 mg/kg/day; however, 28% of levels were above 30 mg/dl. Although there was no evidence of major salycilate toxicity in the group, 3 children receiving >100 mg/kg/day had ASA-induced gastritis. In 11 children significant day to day fluctuation in concentrations was seen. Erratic absorption of ASA was demonstrated in an additional 3 children with KD (age 7-24 mo), studied prospectively. Only 14-20% of their daily ASA dose was recovered in 24 hr urine (normal 80-90%). Serum ASA concentrations were subtherapeutic. The high ASA dose needed to overcome impaired absorption should be accompanied by careful monitoring because of unpredictable absorption changes.